Searching…
Dec 5, 2024 · PURPOSEThe ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than gemcitabine monotherapy. Subsequently, the PRODIGE24-CCTG ...
Mar 11, 2017 · The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic c...
Dec 6, 2024 · Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial Journal: Journal of Clinical Oncology Published: 2024-12-06 DOI: 10.1200/jco.24.01118 Affiliations ...
Jul 19, 2025 · 来自德国海德堡大学的研究团队在《临床肿瘤学杂志》发表ESPAC4试验104个月随访结果，证实吉西他滨联合卡培他滨 (GemCap)方案较单药吉西他滨显著延长胰腺导管腺癌 (PDAC)患者总生存期 (31.6 vs 28.4个月，HR=0.83)，特别在R0切除和淋巴结阴性亚组获益更显著，为不适合mFOLFIRINOX方案患者确立标准治疗选择。
Jun 4, 2016 · ESPAC-1 研究、ESPAC-3 研究中，5FU 单药的获益 5 年 OS 为 21%、吉西他滨对比 5FU 无显著差异，而 ESPAC-4 研究显示吉西他滨联合卡培他滨 5 年 OS 达到 28.8%，为胰腺导管癌患者的治疗带来福音。 敬请关注丁香园的专题报道→ 第 52 届美国临床肿瘤学会（ASCO）年会。
Our aim was to analyze the ESPAC4 survival on long-term follow-up. Methods: The OS of 732 ESPAC4 patients comparing 367 randomly assigned to gemcitabine and 365 to GemCap was previously reported after a median follow-...
Dec 8, 2024 · “The ESPAC4 study reveals promising results in treating pancreatic adenocarcinoma, highlighting the impact of GemCap as an adjuvant therapy compared to gemcitabine. These findings provide valuable insigh...
